Lung Cancer, Non-Hodgkin Lymphoma Biggest Contributors to Life-Years Lost to Cancer in Transplant Patients Lung Cancer, Non-Hodgkin Lymphoma Biggest Contributors to Life-Years Lost to Cancer in Transplant Patients
Transplant recipients have a shortened lifespan after developing cancer, especially those who develop lung cancer and non-Hodgkin lymphoma, according to a new analysis.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - September 22, 2021 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news

Mayo Clinic Q & amp;A podcast: Accurate diagnosis is key to treating lymphoma
Lymphoma is a cancer of the lymphatic system, which is part of the body's germ-fighting network. The lymphatic system includes the lymph nodes or glands, the spleen, the thymus gland, and bone marrow.  While many types of lymphoma exist, the main subtypes are Hodgkin's lymphoma and non-Hodgkin ’s lymphoma. Knowing exactly which type of lymphoma you have is key to developing an effective treatment plan. "The main problem with lymphoma is accurate diagnosis," says Dr. Jose… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 17, 2021 Category: Databases & Libraries Source Type: news

FDA Grants Zanubrutinib an Accelerated Approval in MZL FDA Grants Zanubrutinib an Accelerated Approval in MZL
The US Food and Drug Administration has granted an accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Jeff Bridges Says COVID Made Cancer'Look Like A Piece of Cake'Jeff Bridges Says COVID Made Cancer'Look Like A Piece of Cake '
Actor Jeff Bridges, 71, said Monday that his lymphoma is in remission and that he is feeling better after contracting COVID-19. He was hospitalized for 5 weeks.WebMD Health News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 14, 2021 Category: Cancer & Oncology Tags: Infectious Diseases News Source Type: news

What 9/11 Survivors and First Responders Have Taught Us About Public Health in the 20 Years Since the Attacks
Dr. David Prezant was knocked fully airborne at 9:59 on the morning of Sept. 11, 2001. He didn’t see the impact coming, but he felt it when it hit—and it nearly killed him. Little more than an hour earlier, Prezant, then the deputy chief medical officer of the Fire Department of New York, was headed for his usual workplace at the FDNY’s Office of Medical Affairs, just across the Manhattan Bridge in Brooklyn. He had already heard that a plane had hit the North Tower of the World Trade Center, and he reckoned that it was an accident. By the time he reached his office, however, the South Tower had been struc...
Source: TIME: Health - September 10, 2021 Category: Consumer Health News Authors: Jeffrey Kluger and Tara Law Tags: Uncategorized healthscienceclimate Source Type: news

Dr Reddy's inks pact with Citius Pharma to sell all rights to anti-cancer agent E7777
Dr Reddy's will receive $ 40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to $40 million related to the cutaneous T-cell lymphoma indication approval and up to $70 million for additional indication approvals. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - September 4, 2021 Category: Pharmaceuticals Source Type: news

FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia FDA Approval for Zanubrutinib in Waldenstr öm’s Macroglobulinemia
The US Food and Drug Administration has approved zanubrutinib for use in the treatment of adult patients with a rare form of non-Hodgkin lymphoma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

Consumer Health: What do you know about leukemia and lymphoma?
September is Leukemia and Lymphoma Awareness Month, which makes this a good time to learn about some of the most common types of these two diseases. Leukemia is cancer of the body's blood-forming tissues, including bone marrow and the lymphatic system. Leukemia usually involves the white blood cells, which are potent infection fighters. They normally grow and divide in an orderly way as your body needs them. But in people with leukemia, the bone marrow… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - September 2, 2021 Category: Databases & Libraries Source Type: news

Tisagenlecleucel appears to be cost effective for diffuse large B-cell lymphoma in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Blood cancer symptoms: The sign when you sleep that could signal the deadly disease
THERE are myriad symptoms to look out for when detecting the early stages of blood cancer. These indications differ when determining the nature of blood cancer, whether it is lymphoma, leukaemia myeloma, MDS, MPN or any other classification. However, recent studies have discovered an emerging symptom to look out for during the night. (Source: Daily Express - Health)
Source: Daily Express - Health - August 31, 2021 Category: Consumer Health News Source Type: news

Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function
Chimeric antigen receptor (CAR)–modified T cell therapy is effective in treating lymphomas, leukemias, and multiple myeloma in which the tumor cells express high amounts of target antigen. However, achieving durable remission for these hematological malignancies and extending CAR T cell therapy to patients with solid tumors will require receptors that can recognize and eliminate tumor cells with a low density of target antigen. Although CARs were designed to mimic T cell receptor (TCR) signaling, TCRs are at least 100-fold more sensitive to antigen. To design a CAR with improved antigen sensitivity, we directly compa...
Source: Signal Transduction Knowledge Environment - August 24, 2021 Category: Science Authors: Salter, A. I., Rajan, A., Kennedy, J. J., Ivey, R. G., Shelby, S. A., Leung, I., Templeton, M. L., Muhunthan, V., Voillet, V., Sommermeyer, D., Whiteaker, J. R., Gottardo, R., Veatch, S. L., Paulovich, A. G., Riddell, S. R. Tags: STKE Research Articles Source Type: news

PET radiomics predict relapse in lymphoma patients
There's more to F-18 FDG PET than meets the eye -- especially if radiomics feature...Read more on AuntMinnie.comRelated Reading: PET recommended over bone scintigraphy in pediatric sarcoma PET/CT predicts survival in pancreatic cancer patients PET/CT may predict outcomes in lung cancer surgery PET is useful modality in patients with lymphomas Routine PET field-of-view enough for pediatric lymphoma (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 23, 2021 Category: Radiology Source Type: news

What Does a Lymphoma Skin Rash Look Like?
Title: What Does a Lymphoma Skin Rash Look Like?Category: Diseases and ConditionsCreated: 8/20/2021 12:00:00 AMLast Editorial Review: 8/20/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 20, 2021 Category: Cancer & Oncology Source Type: news

Social Security Adds Pericardial Mesothelioma to Disabilities List
The U.S. Social Security Administration has added pericardial mesothelioma to its Compassionate Allowances list, accelerating the disabilities application process for this very rare cancer. Its decision was prompted by the work of Missy Miller, medical outreach director at The Mesothelioma Center. She made the request with the Social Security disability office almost a year ago on behalf of a patient. The Compassionate Allowances program is reserved for severe medical diseases and conditions that automatically meet Social Security standards for disability benefits. It cuts short the often drawn-out application proces...
Source: Asbestos and Mesothelioma News - August 18, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

What Is the Survival Rate for Follicular Lymphoma?
Title: What Is the Survival Rate for Follicular Lymphoma?Category: Diseases and ConditionsCreated: 8/13/2021 12:00:00 AMLast Editorial Review: 8/13/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 13, 2021 Category: Cancer & Oncology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Media News - August 9, 2021 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form of lymphoma compared to standard of care
Basel, 9 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the pivotal phase III POLARIX trial investigating Polivy ® (polatuzumab vedotin) in combination with MabThera®/Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) versus MabThera/Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), met its primary endpoint by demonstrating significantly improved an d clinically meaningful progression-free survival in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Safety outcomes were consistent with those seen in previous...
Source: Roche Investor Update - August 9, 2021 Category: Pharmaceuticals Source Type: news

Travel-related costs of CAR  T cell therapy high for diffuse large B cell lymphoma in the USA
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - August 1, 2021 Category: Drugs & Pharmacology Source Type: news

What Is Burkitt Lymphoma?
Title: What Is Burkitt Lymphoma?Category: Diseases and ConditionsCreated: 11/20/2015 12:00:00 AMLast Editorial Review: 7/29/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 29, 2021 Category: Cancer & Oncology Source Type: news

Racial Disparities Persist in Multiple Myeloma Care, Outcomes
MONDAY, July 26, 2021 -- There are persistent disparities in multiple myeloma (MM) care for non-Hispanic (NH)-Blacks and Hispanics compared with NH-Whites, according to a study published online July 18 in Leukemia& Lymphoma. Samer Al Hadidi,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 26, 2021 Category: Pharmaceuticals Source Type: news

Phase two CD19-antibody-drug conjugate trial demonstrates promise for aggressive lymphoma
(Medical University of South Carolina) MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2021 Category: Cancer & Oncology Source Type: news

CAR T-Cell Therapy Showing Promise with Pleural Mesothelioma
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment for malignant pleural mesothelioma. The latest step was a clinical trial exploring a first-in-human, intrapleural-administered CAR T-cell therapy used in combination with pembrolizumab, a well-known immunotherapy drug also known by the brand name Keytruda. Results were impressive, including a 23.9-month median overall survival and an 83% one-year survival rate for patients. Cancer Discovery published the single-center study results July 15. “There is ...
Source: Asbestos and Mesothelioma News - July 22, 2021 Category: Environmental Health Authors: Chris Elkins Source Type: news

Studies find combination chemotherapy beneficial and cost-effective in sub-Saharan Africa
(UNC Lineberger Comprehensive Cancer Center) Researchers at the UNC Lineberger Comprehensive Cancer Center demonstrated in a clinical trial in Malawi that a five-drug combination chemotherapy provided curative benefit compared to current standard-of care-therapy in people diagnosed with lymphoma, and now they have determined this option is also cost-effective. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 22, 2021 Category: Cancer & Oncology Source Type: news

Risk for Psoriasis Increased for Cancer Survivors
Increased risks seen for survivors of leukemia, lymphoma, multiple myeloma, skin cancer, and lung cancer in subgroup analyses (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 21, 2021 Category: Cancer & Oncology Tags: Dermatology, Internal Medicine, Oncology, Journal, Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Media News - July 21, 2021 Category: Pharmaceuticals Source Type: news

FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes
Basel, 21 July 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Venclexta ® (venetoclax) in combination with azacitidine has been granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes (MDS) based on the rev ised International Prognostic Scoring System (IPSS-R). MDS are a rare group of blood cancers that gradually affect the ability of the bone marrow to produce normal blood cells.2 This can lead to weakness, frequent infections, anaemia and ...
Source: Roche Investor Update - July 21, 2021 Category: Pharmaceuticals Source Type: news

Zydus Cadila gets tentative nod from USFDA to market cancer drug
"Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia," Zydus Cadila said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 21, 2021 Category: Pharmaceuticals Source Type: news

Blink-182 Bassist Mark Hoppus Reveals He Has Stage 4 Lymphoma Cancer
Blink-182 bassist-singer Mark Hoppus elaborated on his cancer diagnosis during a recent Twitch livestream less than a month after... (Source: Reuters: Health)
Source: Reuters: Health - July 18, 2021 Category: Consumer Health News Source Type: news

FDA Approves First Lymphoma Drug for Dogs
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 16, 2021 Category: Cancer & Oncology Tags: Family Medicine, Oncology, Pharmacy, Research, News, Source Type: news

FDA Approves First Lymphoma Drug for Dogs
FRIDAY, July 16, 2021 -- The first full approval of a drug to treat lymphoma in dogs has been granted by the U.S. Food and Drug Administration. " While canine lymphoma affects fewer than 70,000 dogs in the U.S. annually, it accounts for up to 24% of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 16, 2021 Category: General Medicine Source Type: news

CNIO researchers discover a new pathway to tackle follicular lymphoma
(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The team led by Alejo Efeyan, head of the Metabolism and Cell Signalling Group at the Spanish National Cancer Research Centre (CNIO), has discovered that genetic inhibition of the RagC protein blocks the activation of B lymphocytes and delays the onset of follicular lymphomas without side effects. The study, which was carried out in animal models, was published this week in the journal Cell Reports. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 13, 2021 Category: Cancer & Oncology Source Type: news

FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma
Hematology / Oncology News Burst FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - July 12, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

How I Diagnose Angioimmunoblastic T-Cell Lymphoma How I Diagnose Angioimmunoblastic T-Cell Lymphoma
Diagnosis of angioimmunoblastic T-cell lymphoma is challenging due to its wide clinical and histopathologic spectrum. Review its pathologic features and a path to accurate diagnosis in this paper.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 8, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Viracta Therapeutics Announces the Appointment of Ayman El-Guindy, Ph.D., as Chief Scientific Officer and Key Additions to Management Team
SAN DIEGO, July 6, 2021 -- (Healthcare Sales & Marketing Network) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Ayman El-Guindy, Ph.D., as Chief Scien... Biopharmaceuticals, Personnel Viracta Therapeutics, nanatinostat, Epstein-Barr, lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 6, 2021 Category: Pharmaceuticals Source Type: news

NYUAD study maps nanobody structure, leading to new ways to potentially fight diseases
(New York University) For the first time in the UAE, researchers at NYU Abu Dhabi have used nuclear magnetic resonance techniques to determine the structure of a specific nanobody, Nb23, potentially leading to a better understanding of how this small protein derived from an antibody type, found only in camelids (i.e camels, llamas, and alpacas) and sharks, can fight diseases ranging from rheumatoid arthritis, lupus and psoriasis to lymphoma and breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 2, 2021 Category: Cancer & Oncology Source Type: news

FDA Approves Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

FDA Approves Rylaze for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
DUBLIN, June 30, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) for use as a component of a... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 30, 2021 Category: Drugs & Pharmacology Source Type: news

Real-World CAR T Outcomes for DLBCL Mimic Clinical Trials Real-World CAR T Outcomes for DLBCL Mimic Clinical Trials
Data from a large French registry suggest that the favorable outcomes in aggressive lymphoma seen in clinical trials can be replicated in the real world.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

EMA Panel OKs Two New Drugs for Blood Cancers EMA Panel OKs Two New Drugs for Blood Cancers
The CHMP has recommended conditional marketing authorization for idecabtagene vicleucel for multiple myeloma and tafasitamab for lymphoma.International Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Autophagy in Hematological Malignancies Autophagy in Hematological Malignancies
This review examines the autophagy pathway and its role in the development of hematological malignancies, with a focus on myeloid and lymphoid leukemia and lymphoma.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

Risk of ALCL After Breast Implant Insertion Risk of ALCL After Breast Implant Insertion
If late seroma develops after breast implant insertion, is there a greater risk for anaplastic large-cell lymphoma?ePlasty (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 23, 2021 Category: Consumer Health News Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news

Researchers discover a novel class of drugs that may help treat a deadly type of lymphoma
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A new class of drugs that inhibits a 'master switch' involved in the vast majority of cases of mantle cell lymphoma (MCL), a fatal subtype of non-Hodgkin's lymphoma, has been discovered by researchers at Mount Sinai. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 22, 2021 Category: Biology Source Type: news

Bayer-submits-regulatory-applications-oncology-treatment-combination-copanlisib-rituximab-US-EU
In the US, Bayer has filed for relapsed indolent B-cell non-Hodgkin’s lymphoma (B-iNHL) / In the EU, Bayer has filed for relapsed marginal zone lymphoma (MZL), a subtype of iNHL, and the filing has been accepted / Filings based on results from Phase III trial CHRONOS-3 showing a significant improvement in the primary endpoint of progression-free survival for the combination of copanlisib and rituximab in patients with relapsed iNHL (Source: Bayer Company News)
Source: Bayer Company News - June 21, 2021 Category: Pharmaceuticals Source Type: news

How the surfaces of silicone breast implants affect the immune system
(Massachusetts Institute of Technology) A team led by MIT researchers analyzed how the surface topography on silicone breast implants influences health complications such as scarring, inflammation, and a rare type of lymphoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 21, 2021 Category: Cancer & Oncology Source Type: news

Prolonged COVID-19 Common Among Patients With Lymphoma Prolonged COVID-19 Common Among Patients With Lymphoma
Approximately a third of patients with B-cell non-Hodgkin lymphoma require hospitalization for COVID-19 beyond 30 days. Older age and anti-CD20 therapy are key risk factors.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 18, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Foresight diagnostics to show vision of the new standard of lymphoma MRD detection at ICML
(Samba Scientific) Forsight to present clinical data of their blood-based MRD detection platform for DLBCL that detects relapse 200 days earlier than other methods. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 17, 2021 Category: International Medicine & Public Health Source Type: news

Blood cancer patients with COVID-19 fare better with convalescent plasma
(Washington University in St. Louis) A large, retrospective, multicenter study involving Washington University School of Medicine in St. Louis indicates that convalescent plasma from recovered COVID-19 patients can dramatically improve likelihood of survival among blood cancer patients hospitalized with the virus. The therapy involves transfusing plasma -- the pale yellow liquid in blood that is rich in antibodies -- from people who have recovered from COVID-19 into patients who have leukemia, lymphoma or other blood cancers and are hospitalized with the viral infection. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 17, 2021 Category: Cancer & Oncology Source Type: news

' Impressive Results' With CAR T-cell in R/R Follicular Lymphoma'Impressive Results' With CAR T-cell in R/R Follicular Lymphoma
Updated results show that patients who received the novel CAR T-cell therapy had significantly improved overall survival than comparable patients who received other current therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 15, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Durham company sees promise in clinical trials for leukemia treatment
A gene therapy company's interim clinical trial results for a leukemia treatment have company executives optimistic about the treatment's future. Durham-based Precision BioSciences (Nasdaq: DTIL) last week announced the interim results of the phase 1/2a trial for PBCAR0191, which showed 75 percent of the study participants with treatment-resistant non-Hodgkins lymphoma responded to the company's treatment. PBCAR0191 is an allogeneic chime ric antigen receptor T cell, or CAR-T, therapy that uses… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 14, 2021 Category: American Health Authors: Sonia Waraich Source Type: news

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duratio...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news